Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Icotrokinra: First Approval.

Drugs·2026
Same author

Ferric Maltol: Pediatric First Approval.

Paediatric drugs·2026
Same author

Sevabertinib: First Approval.

Drugs·2026
Same author

Retlirafusp Alfa: First Approval.

Drugs·2026
Same author

Zeprumetostat: First Approval.

Drugs·2025
Same author

Brensocatib: First Approval.

Drugs·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
查看所有相关文章

相关实验视频

Updated: Jun 7, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K

阿克萨提利马布:首次获得批准

Susan J Keam1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|November 17, 2024
PubMed
概括
此摘要是机器生成的。

阿克萨利利马布是一种新的单克隆抗体,已批准用于慢性移植对宿主疾病 (cGVHD) 的患者,这些患者对其他治疗没有反应. 这标志着cGVHD治疗的重大进展.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

995

相关实验视频

Last Updated: Jun 7, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

995

科学领域:

  • 免疫学 免疫学 免疫学
  • 血液学 血液学 血液学
  • 在瘤学瘤学.

背景情况:

  • 慢性移植对宿主疾病 (cGVHD) 是异构干细胞移植后的一种严重并发症.
  • 现有的cGVHD治疗方法存在局限性,需要新的治疗方法.
  • 殖民地刺激因子1受体 (CSF-1R) 在巨细胞生物学中起着与cGVHD病变发生相关的作用.

研究的目的:

  • 总结一下axatilimab的发展里程碑.
  • 为了突出最近美国FDA批准axatilimab用于cGVHD治疗.
  • 为了记录axatilimab在cGVHD.cGVHD的NCCN指南中的包括.

主要方法:

  • 阿克萨利利马布是一种人性化的IgG4单克隆抗体,向CSF-1R.
  • 临床开发的重点是对先前的全身疗法耐药的cGVHD患者.
  • 基于临床疗效和安全数据的监管审查和指导方针的包含.

主要成果:

  • 阿克萨利利马布在2024年8月获得美国FDA批准,用于至少两种先前治疗线后患有cGVHD (≥40公斤) 的成人和儿科患者.
  • 阿克萨提利马布代表了这种特定患者群体的首次批准.
  • 阿克萨提利马布于2024年8月被纳入cGVHD的NCCN指南中.

结论:

  • 阿克萨提利马布的批准意味着对耐火性cGVHD患者的重大治疗进展.
  • 阿克萨提利马布的向机制为管理这种具有挑战性的疾病提供了新的选择.
  • 纳入NCCN指南强调了其临床意义和推使用.